Muthiah Vaduganathan, MD, MPH

Phase 3 FIND-CKD data show finerenone slows kidney function decline in non-diabetic chronic kidney disease, extending the agent's role beyond diabetic CKD.

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Learn how uACR and eGFR tracking, EHR prompts, and team-based titration streamline early CKD care and reduce cardiovascular risk.

See how UACR trends motivate patients, guide shared decisions, and tailor therapies to slow CKD while lowering cardiovascular risk.

Heart failure playbook reshapes CKD care: early combo therapies, right dosing, and smart uACR/eGFR follow-up to boost adherence.

Explore the four-pillars approach to slowing kidney disease—max dose ACE/ARB, add SGLT2, MRA, GLP‑1—plus access and team-based tips.

Learn how KDIGO risk staging and urine ACR guide CKD management, triage, and timely nephrology referral when red flags appear.

Clinicians rethink cardio-renal care: educate teams, streamline workflows, expand screening via pharmacists and EHRs, and prioritize prevention over dialysis.

Why uACR urine testing lags: incentives, workflow gaps, and silos—and how KDIGO staging strengthens kidney and cardiovascular risk conversations.

Learn why pairing eGFR with urine albumin-creatinine ratio improves CKD screening, avoids missed diagnoses, and guides follow-up care.

Learn how UACR testing complements eGFR, reveals hidden kidney and cardiovascular risk, and uses a color-coded heat map to guide patient communication and referrals.

Clinicians across specialties share responsibility for early kidney disease screening—use UACR and eGFR at every touchpoint to prevent patients slipping through cracks.

Why CKD screening lags despite aligned KDIGO, ADA and hypertension guidance—use eGFR plus UACR staging and EHR prompts to act earlier.

CKD guidelines agree: use eGFR plus UACR for KDIGO staging, but screening lags—see how teams and EHRs close the gap.

Experts explain how uACR and eGFR testing reveals hidden CKD, links to heart risk, and guides early, patient-centered care.

Learn how uACR and eGFR uncover hidden CKD, sharpen cardiovascular risk, and guide patient-friendly conversations for earlier, smarter care.

This Heart Failure Awareness Week, revisit recent advancements and scope out the future of heart failure care with HCPLive.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, sat down with Ambarish Pandey, MD, to discuss the revolutionary POLY-HF trial and how polypills can fit into heart failure treatment.

Neuen is joined by Richard Pratley, MD, and Muthiah Vaduganathan, MD, MPH, to discuss the evolving landscape of CKM trial design.

Explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Javed Butler, MD, to discuss the results of this major trial.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Darren McGuire, MD, to discuss the results of this groundbreaking trial.

Panelists discuss differentiators between nsMRA and steroidal MRAs in the context of heart failure.

Panelists offer perspective on the role of finerenone in combination therapy approaches in patients with HFmrEF/HFpEF.

Finerenone's FDA approval marks a transformative step in heart failure treatment, offering early benefits and broad applicability.

Finerenone's FDA approval marks a breakthrough in heart failure treatment, significantly reducing cardiovascular events and hospitalizations for patients.

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.

Hosts explore the latest advancements in amyloidosis treatment, with expert insights on emerging therapies and patient care strategies.

Hosts discuss how recent advances in HFpEF have changed discussions surrounding how cardiologists should approach treatment sequencing.